These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21863402)

  • 21. Carrier screening for cystic fibrosis.
    Massie J
    Lancet; 2009 Sep; 374(9694):978. PubMed ID: 19766881
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process.
    Ciske DJ; Haavisto A; Laxova A; Rock LZ; Farrell PM
    Pediatrics; 2001 Apr; 107(4):699-705. PubMed ID: 11335747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.
    Langfelder-Schwind E; Karczeski B; Strecker MN; Redman J; Sugarman EA; Zaleski C; Brown T; Keiles S; Powers A; Ghate S; Darrah R
    J Genet Couns; 2014 Feb; 23(1):5-15. PubMed ID: 24014130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highlighting the impact of cascade carrier testing in cystic fibrosis families.
    Duguépéroux I; L'Hostis C; Audrézet MP; Rault G; Frachon I; Bernard R; Parent P; Blayau M; Schmitt S; Génin E; Férec C; Scotet V
    J Cyst Fibros; 2016 Jul; 15(4):452-9. PubMed ID: 27013383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shock, adjust, decide: reproductive decision making in cystic fibrosis (CF) carrier couples--a qualitative study.
    Myring J; Beckett W; Jassi R; Roberts T; Sayers R; Scotcher D; McAllister M
    J Genet Couns; 2011 Aug; 20(4):404-17. PubMed ID: 21732237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principles and practicalities of carrier screening: attitudes of recent parents.
    Green JM
    J Med Genet; 1992 May; 29(5):313-9. PubMed ID: 1583658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystic fibrosis carrier testing in early pregnancy by general practitioners.
    Harris H; Scotcher D; Hartley N; Wallace A; Craufurd D; Harris R
    BMJ; 1993 Jun; 306(6892):1580-3. PubMed ID: 8329921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of preconceptional and prenatal cystic fibrosis carrier screening: a systematic review.
    Banzi R; Allocati E; Gerardi C; Castellani C; Rissone M; Stracuzzi M; Ferrario L; Foglia E; Mosconi P; Colombo C
    Epidemiol Prev; 2023; 47(4-5):243-256. PubMed ID: 37846447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 10-year large-scale cystic fibrosis carrier screening in the Italian population.
    Picci L; Cameran M; Marangon O; Marzenta D; Ferrari S; Frigo AC; Scarpa M
    J Cyst Fibros; 2010 Jan; 9(1):29-35. PubMed ID: 19897426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active cascade testing for carriers of cystic fibrosis gene.
    Super M; Schwarz MJ; Malone G; Roberts T; Haworth A; Dermody G
    BMJ; 1994 Jun; 308(6942):1462-7. PubMed ID: 8019278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new ethical landscape of prenatal testing: individualizing choice to serve autonomy and promote public health: a radical proposal.
    Munthe C
    Bioethics; 2015 Jan; 29(1):36-45. PubMed ID: 25521972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic fibrosis carrier screening in a high-risk population. Participation based on a traditional recruitment process.
    Surh LC; Cappelli M; MacDonald NE; Mettler G; Dales RE
    Arch Pediatr Adolesc Med; 1994 Jun; 148(6):632-7. PubMed ID: 8193692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CF carrier testing in a high risk population: anxiety, risk perceptions, and reproductive plans of carrier by "non-carrier" couples.
    Callanan NP; Cheuvront BJ; Sorenson JR
    Genet Med; 1999; 1(7):323-7. PubMed ID: 11263543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limits to the scope of non-invasive prenatal testing (NIPT): an analysis of the international ethical framework for prenatal screening and an interview study with Dutch professionals.
    Kater-Kuipers A; Bunnik EM; de Beaufort ID; Galjaard RJH
    BMC Pregnancy Childbirth; 2018 Oct; 18(1):409. PubMed ID: 30340550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prenatal screening: current practice, new developments, ethical challenges.
    de Jong A; Maya I; van Lith JM
    Bioethics; 2015 Jan; 29(1):1-8. PubMed ID: 25521968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for cystic fibrosis and its evaluation.
    Wildhagen MF; ten Kate LP; Habbema JD
    Br Med Bull; 1998; 54(4):857-75. PubMed ID: 10367419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystic fibrosis mutation testing in Italy.
    Bombieri C; Pignatti PF
    Genet Test; 2001; 5(3):229-33. PubMed ID: 11788089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prenatal screening for cystic fibrosis carriers: an economic evaluation.
    Rowley PT; Loader S; Kaplan RM
    Am J Hum Genet; 1998 Oct; 63(4):1160-74. PubMed ID: 9758600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs, effects, and savings of screening for cystic fibrosis gene carriers.
    Wildhagen MF; Hilderink HB; Verzijl JG; Verheij JB; Kooij L; Tijmstra T; ten Kate LP; Habbema JD
    J Epidemiol Community Health; 1998 Jul; 52(7):459-67. PubMed ID: 9799881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct marketing of cystic fibrosis carrier screening: commercial push or population need?
    Cuckle H; Lilford R; Wilson J; Sehmi I
    J Med Genet; 1995 Sep; 32(9):758. PubMed ID: 8544204
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.